News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: New Data On Safety And Efficacy Of Pradaxa® In Treatment Of Acute Deep Vein Thrombosis And Pulmonary Embolism


12/17/2013 9:47:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only

New pooled safety data from the RE-COVERTM and RE-COVERTM II phase III trials in acute deep vein thrombosis (DVT) and pulmonary embolism (PE) consistently favour treatment with Pradaxa® 150mg bid over treatment with warfarin. The data are published online today in Circulation.1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES